TY - JOUR
T1 - Switching tenofovir disoproxil fumarate to tenofovir alafenamide results in a significant decline in parathyroid hormone levels
T2 - uncovering the mechanism of tenofovir disoproxil fumarate-related bone loss?
AU - Van Welzen, Berend J
AU - Thielen, Matheus A J
AU - Mudrikova, Tania
AU - Arends, Joop E
AU - Hoepelman, Andy I M
PY - 2019/7/15
Y1 - 2019/7/15
N2 - : An increasing number of patients have been switched from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide because of its improved bone safety profile, although the pathophysiological mechanism is not fully understood. We show that serum parathyroid hormone levels drop significantly after the switch from TDF to tenofovir alafenamide. This observation supports the theories that TDF-related bone loss is parathyroid hormone-driven and that this effect is dose-dependent.
AB - : An increasing number of patients have been switched from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide because of its improved bone safety profile, although the pathophysiological mechanism is not fully understood. We show that serum parathyroid hormone levels drop significantly after the switch from TDF to tenofovir alafenamide. This observation supports the theories that TDF-related bone loss is parathyroid hormone-driven and that this effect is dose-dependent.
UR - http://www.scopus.com/inward/record.url?scp=85069237751&partnerID=8YFLogxK
U2 - 10.1097/QAD.0000000000002238
DO - 10.1097/QAD.0000000000002238
M3 - Article
C2 - 31021851
SN - 0269-9370
VL - 33
SP - 1531
EP - 1534
JO - AIDS
JF - AIDS
IS - 9
ER -